DrugPatentWatch Database Preview
Patent: 8,741,929
» See Plans and Pricing
Summary for Patent: 8,741,929
| Title: | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
| Abstract: | Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid.RTM. or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed. |
| Inventor(s): | Zeldis; Jerome B. (Princeton, NJ) |
| Assignee: | Celgene Corporation (Summit, NJ) |
| Application Number: | 12/621,502 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,741,929 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,741,929
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Celgene Corporation (Summit, NJ) | 2026-08-03 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Celgene Corporation (Summit, NJ) | 2026-08-03 | RX | Orphan | search |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | Celgene Corporation (Summit, NJ) | 2026-08-03 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | Celgene Corporation (Summit, NJ) | 2026-08-03 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,741,929
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008019065 | Start Trial |
| United States of America | 2008038263 | Start Trial |
| United States of America | 2010068206 | Start Trial |
| United States of America | 2014271638 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
